Search results
Results from the WOW.Com Content Network
The journal was established in 1988 (ISSN 0894-9255). [1]It was retitled Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology (ISSN 1077-9450) in 1995, returning to the title Journal of Acquired Immune Deficiency Syndromes in 1999.
An article processing charge (APC), also known as a publication fee, is a fee which is sometimes charged to authors. Most commonly, it is involved in making an academic work available as open access (OA), in either a full OA journal or in a hybrid journal .
A nuisance fee is a fee, fine, or penalty which is charged to deter an action, rather than to compensate for the costs of that action. [1] For example, a five-dollar penalty for submitting an application late does not compensate for costs associated with processing late submissions, but rather encourages people to submit on time.
Fee-based open access publishing has been criticized on quality grounds, as the desire to maximize publishing fees could cause some journals to relax the standard of peer review. Although, similar desire is also present in the subscription model, where publishers increase numbers or published articles in order to justify raising their fees.
Something happened, and you need money. Urgently. You look at your savings account. Tumbleweeds roll across the place your emergency fund should occupy. Meanwhile, your credit card beckons with ...
For products launching after the submission deadline, please contact ghbeautyinnovationawards@hearst.com regarding final packaging availability and arrangement for possible later product submission.
(Reuters) -The U.S. Supreme Court denied on Tuesday a bid by former independent presidential candidate Robert F. Kennedy Jr., who has endorsed Republican Donald Trump, to be removed from the ...
Regulated Product Submission (RPS) is a Health Level Seven (HL7) standard designed to facilitate the processing and review of regulated product information. [1] RPS is being developed in response to performance goals that the U.S. Food and Drug Administration (FDA) is to achieve by 2012, as outlined in the Prescription Drug User Fee Act (PDUFA). [2]